TALVIRALINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H20N2O3S2
Molecular Weight	340.461
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=C(NC(=S)[C@H](CSC)N2C(=O)OC(C)C)C=C1

InChI

InChIKey=GWKIPRVERALPRD-ZDUSSCGKSA-N

InChI=1S/C15H20N2O3S2/c1-9(2)20-15(18)17-12-7-10(19-3)5-6-11(12)16-14(21)13(17)8-22-4/h5-7,9,13H,8H2,1-4H3,(H,16,21)/t13-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C15H20N2O3S2
Molecular Weight	340.461
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8619578 | https://www.ncbi.nlm.nih.gov/pubmed/9952383

Talviraline (HBY 097) was developed as a nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (NNRTI) for the treatment of HIV Infections. Talviraline participated in a phase II clinical trial. It was found that the drug caused pronounced acute suppression of HIV-1 replication both in combination with zidovudine and alone. However, further development of the drug has been discontinued.

Approval Year

PubMed

Title	Date	PubMed
In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.	1997 Apr 28	9143309
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.	1997 Nov	9343170
Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride.	1998 Dec	9835502
Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent.	1998 Jul 9	9677161
Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).	1998 Mar 1	9515572
Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.	1999 Oct 7	10514285

Sample Use Guides

In Vivo Use Guide

HBY 097 (TALVIRALINE) monotherapy (250 mg three times daily)

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:06:14 UTC 2023` Edited by `admin` on `Fri Dec 15 16:06:14 UTC 2023`
Record UNII	XZ4KT6MO4X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TALVIRALINE

Official Name

English

Talviraline [WHO-DD]

Common Name

English

TALVIRALINE [MART.]

Common Name

English

1(2H)-QUINOXALINECARBOXYLIC ACID, 3,4-DIHYDRO-7-METHOXY-2-((METHYLTHIO)METHYL)-3-THIOXO-, 1-METHYLETHYL ESTER, (2S)-

Systematic Name

English

HBY-097

Code

English

3,4-DIHYDRO-7-METHOXY-2-((METHYLTHIO)-METHYL)-3-THIOXO-1(2H)-QUINOXALINECARBOXYLIC ACID 1-METHYLETHYL ESTER, S-

Systematic Name

English

ISOPROPYL (2S)-3,4-DIHYDRO-7-METHOXY-2-((METHYLTHIO)METHYL)-3-THIOXO-1(2H)-QUINOXALINECARBOXYLATE

Systematic Name

English

HBY097

Code

English

talviraline [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C97453